Respiratory Muscle Fatigue and Lower Extremity Muscle Oxygenation

Medipol Health Group

Status

Enrolling

Conditions

COPD

Treatments

Other: Respiratory muscle fatigue protocol

Study type

Interventional

Funder types

Other

Identifiers

NCT06217276

Respiratory muscle fatigue&VL

Details and patient eligibility

About

In our study, changes in vastus lateralis muscle oxygenation will be evaluated with the Moxy device, a functional infrared oxygen measurement device, during the inspiratory muscle fatigue protocol in COPD cases and the healthy control group.

Enrollment

30 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Having a diagnosis of Stage 2-3 COPD according to the following clinical diagnostic criteria according to the American Thoracic and European Respiratory Societies (ATS-ERS).
Having been using the same medications for the last 4 weeks

Exclusion criteria

Patients with severe comorbid diseases, unstable coronary artery disease, collagen vascular diseases and requiring high-flow oxygen therapy (˃ 3-4 L\min).
Presence of any vascular problem that may affect lower extremity muscle oxygenation
Presence of another respiratory system disease other than COPD
Patients who have had an acute COPD exacerbation in the last 4 weeks
Patients experiencing COPD exacerbations during the study protocol
Presence of fatty tissue or scar tissue at the measurement points, which may impair the measurement quality.
Have already participated in another clinical trial within the last 30 days that may affect the results of the study.

Inclusion Criteria for Healthy Cases